ATOMO DIAGNOSTICS LIMITED — Capital/Financing Update 2023

Aug 7, 2023

==> picture [75 x 73] intentionally omitted <==

Atomo completes successful Capital Raising

8 August 2023

Sydney, Australia, 8 August 2023 : Atomo Diagnostics Limited (ASX:AT1) ( Atomo or the Company ) is pleased to announce the completion of its placement and SPP which raised a total of $2.25m.

The capital raising comprised three components:

• A Placement to sophisticated and institutional investors to raise ~$1.25m at a price of $0.036 per new share which, as announced on 13 July 2023

• A Share Purchase Plan (SPP) to Eligible Shareholders that raised ~$0.46m at a price of $0.03 per share which closed on 1 August 2023

• An SPP shortfall placement to institutional investors on the same terms as the SPP to raise ~$0.54m

All valid SPP applications were accepted in full.

Atomo CEO and Managing Director, John Kelly said:

“We are grateful for the ongoing support of our existing shareholders and welcome the new shareholders who participated in the placement. With the capital raising now completed, we are well positioned to accelerate our commercial rollout and move ahead with the next phase of growth for Atomo.”

Under the SPP, new shares were offered at the lower of A$0.036 and a 2.5% discount to the VWAP of shares traded on the ASX during the five trading days up to the closing date of the SPP, rounded to the nearest half cent.

As at the closing date, the Company had received valid applications for ~$0.46m worth of New Shares under the SPP and the SPP shares were issued at $0.03 per share (SPP

Price), representing a 2.5% discount to the volume weighted average price of shares during

Atomo Diagnostics Limited Level 1, 3-5 George St Leichhardt NSW 2040 ACN 142 925 684

==> picture [75 x 73] intentionally omitted <==

the five trading days up to and including the closing date of the SPP. The SPP price satisfies the conditions in ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 and therefore the Company can rely on Exception 5 to ASX Listing Rule 7.1 and Exception 4 to ASX Listing Rule 10.11 to issue shares under the SPP without shareholder approval.

As announced on 13 July 2023, the Company received binding commitments for a placement of up to A$1m at the same price as the SPP in the event that less than A$1m was raised under the SPP. The Company has therefore raised a further ~$0.56m by way of placement to cover the difference between the SPP commitments received and the shortfall placement commitment (“Shortfall Placement”). Shortfall Placement shares are issued at the same price as the SPP.

In accordance with the SPP timetable and subject to ASX confirmation, quotation of the SPP shares including the Shortfall Placement shares is expected to occur on 9 August 2023.

Proceeds raised under the Placement and SPP will be used to expand and accelerate sales, marketing, business development and new product registration activities focusing on revenue generating activities.

All shares issued under the Placement and SPP will rank equally with existing fully paid shares in Atomo.

Bell Potter Securities Limited was sole Lead Manager and bookrunner to the capital raising.

This announcement was authorised by the Managing Director

.

-Ends-

For more information, please contact:

John Kelly Atomo Diagnostics

john.kelly@atomodiagnostics.com Phone: +61 401 922 279

Level 1, 3-5 George St Leichhardt NSW 2040

Atomo Diagnostics Limited ACN 142 925 684

==> picture [75 x 73] intentionally omitted <==

About Atomo

Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health.

See more at www.atomodiagnostics.com.

Disclaimer

The information in this announcement does not constitute investment or financial product advice (nor tax, accounting or legal advice) nor any recommendation to acquire new shares in Atomo. It does not take into account any individual’s investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek appropriate advice, including financial, legal, accounting and taxation advice appropriate to their jurisdiction. Atomo is not licensed to provide financial product advice in respect of the new shares.

This announcement is not and should not be considered an invitation or offer to acquire or sell shares in Atomo or any other financial products, or a solicitation to invest in or refrain from investing in shares in Atomo or any other financial products. This announcement is for information purposes only and it is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or any other law.

Not for release to US wire services or distribution in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

Level 1, 3-5 George St Leichhardt NSW 2040

Atomo Diagnostics Limited ACN 142 925 684